Covid update: Pfizer says it will have the ability to supply 1.3bn vaccine doses by the end of next year (if trials and approvals go to plan)

The update was provided in after-hours data reveal by the pharma giant and its partner BioNTech SE

Pfizer -

Pfizer Inc (NYSE:PFE) said the COVID-19 drug it is jointly developing with BioNTech SE could be ready for regulatory scrutiny by October.

On that timeline, the pair could have 100mln dose ready by the end of the year, with the ability to supply 1.3bn doses by the end of next year.

The details were provided alongside new data released after hours from the trial of BNT162b2, an mRNA-based vaccine, that is now in phase II/III.

The latest update, taken from the phase I stage, revealed the drug candidate had “promising” safety and immunogenicity profile. Immunogenicity refers to BNT162b2’s ability to provoke an immune response.

In July, the US government has agreed to pay Pfizer and BioNTech US$1.95bn to secure access to 100mln doses of their coronavirus vaccine.

The deal was part of the Trump administration’s Operation Warp Speed that aims to deliver 300mln vaccines by early 2021.

Pfizer shares were trading higher pre-market.

Quick facts: Pfizer

Price: 39.41 USD

Market: NYSE
Market Cap: $219.06 billion

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...


Clarity Gold Corp focus turns to Quebec with the acquisition of the Destiny...

Clarity Gold Corp (CSE: CLAR- OTC: CLGCF) CEO James Rogers joined Steve Darling from Proactive with news the company has made a major acquisition in the Quebec region picking a very interesting project called Destiny. Rogers talked about what they liked about the project and some of the work...

2 hours, 11 minutes ago

2 min read